Compare · NTBL vs NVO
NTBL vs NVO
Side-by-side comparison of Notable Labs Ltd. (NTBL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTBL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- NVO has hit the wire 5 times in the past 4 weeks while NTBL has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for NTBL).
- Company
- Notable Labs Ltd.
- Novo Nordisk A/S
- Price
- $0.25-29.15%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- -
- +13.32%
- 1Y return
- -
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 5
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NTBL
- Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update
- New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)
- Notable Labs downgraded by JMP Securities
- Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Notable Labs Ltd. filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form S-1/A filed by Notable Labs Ltd.
- Notable Labs to Present Data on September 4th at SOHO 2024
- Amendment: SEC Form S-1/A filed by Notable Labs Ltd.
- Notable Labs Ltd. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S